TABLE 2.
Summary of Modeled Outcomes Among Biomarker-Prevalent Patients
| Input/analysis | Observed Practice | Optimal Practice | Incremental harms (net Observed vs Optimal) |
|---|---|---|---|
| Base case | |||
| Appropriately treated | 28,177 | 46,757 | No harms |
| Missed PMTT | 21,250 | 2,670 | 18,580 missed |
| Total LY | 92,516 | 113,417 | 20,902 LYL |
| Prevalence of actionable biomarker uncertainty | |||
| Appropriately treated | 12,158-28,177 | 20,175-46,757 | No harms |
| Missed PMTT | 9,169-21,250 | 1,152-2,670 | 8,017-18,580 missed |
| Total LY | 39,920-92,516 | 48,938-113,417 | 9,018-20,901 LYL |
| PMTT following guideline-consistent testing uncertainty | |||
| Appropriately treated | 20,763-32,626 | 46,757 | No harms |
| Missed PMTT | 16,801-28,663 | 2,670 | 14,131-25,993 missed |
| Total LY | 84,175-97,520 | 113,417 | 15,897-29,242 LYL |
| Targeted testing in current practice | |||
| Appropriately treated | 26,643-29,712 | 46,757 | No harms |
| Missed PMTT | 19,715-22,785 | 2,670 | 17,045-20,115 missed |
| Total LY | 90,790-94,243 | 113,417 | 19,174-22,628 LYL |
| Overall survival (PMTT), median | |||
| Appropriately treated | No impact | No impact | No impact |
| Missed PMTT | No impact | No impact | No impact |
| Total LY | 79,601-106,135 | 91,987-136,016 | 12,386-29,882 LYL |
| Overall survival (nontargeted treatment), median | |||
| Appropriately treated | No impact | No impact | No impact |
| Missed PMTT | No impact | No impact | No impact |
| Total LY | 86,632-99,328 | 113,417 | 14,089-26,785 LYL |
Values are presented as a range or n.
LY = life-years; LYL = life-years lost; PMTT = precision-matched targeted therapy.